[18F]F-AraG PET Imaging in Alzheimer's Disease
ConditionAlzheimer Disease (AD)
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age55+
SponsorCellSight Technologies, Inc.
About this trial
This study evaluates the use of \[18F\]F-AraG PET/CT imaging to quantify activated T cell involvement in patients with Alzheimer's disease (AD). Participants will undergo total-body dynamic PET imaging to assess tracer uptake in the brain and peripheral organs. Results will be compared between participants with AD and healthy controls to characterize both central nervous system and systemic immune alterations in AD
Eligibility criteria
Qualifiers
Age ≥ 55 years
Prior volumetric brain MRI available. If the prior MRI scan is not acquired within 6 months of [18F]F-AraG imaging or if the investigator determines that prior MRI scan cannot be used, a new MRI scan will be acquired.
Able to tolerate a PET scan, and willingness and ability to comply with all protocol required procedures.
For participants of reproductive potential - defined as individuals who have not been post-menopausal for at least 24 consecutive months (i.e., who have had menses within the preceding 24 months), or who have not undergone surgical sterilization, specifically hysterectomy and/or bilateral oophorectomy or bilateral salpingectomy - willingness to use effective double barrier contraceptive methods (excluding withdrawal or timing methods) up to 1 day after the administration of [18F]F-AraG
Disqualifiers
Clinically significant psychiatric disease other than depression.
Structural brain abnormalities on MRI (e.g. large infarct or mass) likely to interfere with interpretation of a PET scan.
History of significant alcohol or substance abuse/dependence within the past 5 years.
Non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the PET imaging session.
Trial design
Treatments tested in this trial
- Drug: [18F]F-AraG (PET tracer)
Treatment groups
10 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
CellSight Technologies, Inc.
Lead sponsor
University of California, Davis
Collaborator
Source ClinicalTrials.gov